Adverum Biotechnologies Inc
0.87 - 0.8999
0.7954 - 3.86
Join Discuss about ADVM with like-minded investors
Next Dividend Date
Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema.
CEO: Leone Patterson
HQ: 800 Saginaw Drive Redwood City, 94063 California